teaser
Boehringer Ingelheim has announced the upcoming presentation of data from 14 abstracts involving three of the company’s investigational oncology compounds – afatinib, nintedanib and volasertib.
Results, to be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, 31 May – 4 June, 2013, are from Boehringer Ingelheim’s robust oncology pipeline. These data presentations demonstrate the company’s ongoing commitment to improving patients’ lives through the research and development of new treatment options, based on the latest advances in the field of oncology.
Data include new results from two pivotal Phase III trials of nintedanib and new Phase III results for afatinib across different advanced non-small cell lung cancer (NSCLC) subtypes:
The LUME-Lung 1 trial (abstract #LBA8011): Phase III pivotal trial data evaluating nintedanib in combination with standard second-line chemotherapy (docetaxel) in patients with advanced NSCLC after failure of first-line chemotherapy. This presentation was accepted as a late-breaker.
The LUME-Lung 2 trial (abstract #8034): evaluating nintedanib in combination with standard chemotherapy (pemetrexed) in patients with advanced NSCLC after failure of first-line chemotherapy.
The LUX-Lung 6 trial, the largest prospective registration trial in EGFR mutation positive lung cancer patients, (abstracts #8016 & 8061): evaluating afatinib compared to a standard chemotherapy (gemcitabine and cisplatin) as first-line treatment in Asian patients with advanced NSCLC who have an epidermal growth factor receptor (EGFR) mutation.
“We are excited to present data from three of our proprietary late stage development compounds in four different cancer indications, which underlines our determination to advance therapies in oncology,” said Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “Our extensive research programme is an expression of our dedication to improving outcomes for cancer patients through targeted treatment.”
